Fidelis Pharmaceuticals, Inc., offers exceptional expertise in the acquisition, development, and marketing of unique pharmaceutical formulations that meet specialized veterinary needs.
Fidelis Pharmaceuticals is a privately held U.S.-based company serving the world from the Northeast pharmaceutical corridor:
- Company headquarters is located in New Jersey.
- Ethiqa XR is manufactured in Pennsylvania.
- Supply chain sources and manufacturing sites and operations are in full compliance with current Good Manufacturing Practices (cGMPs) regulated by the FDA.
- Dedicated to providing products that are indexed by the FDA.
The Fidelis Pharmaceuticals Team of Experts
Our leadership team possesses a wealth of experience in developing innovative, effective pharmaceutical solutions for veterinary medicine.
The Fidelis team applies specialized product development and manufacturing expertise to formulate reliable, cGMP-quality products uniquely suited to meet veterinary needs.
Barry Levinson, PhD
Co-Founder, Chief Operating Officer
Barry Levinson, PhD, serves as Chief Operating Officer with Fidelis Pharmaceuticals. Dr. Levinson has over 35 years of biotech and pharmaceutical industry experience combined with a distinguished scientific career. He previously served as VP Business Development at Valeant Pharma (now Bausch Health) and was a founding employee, VP Business Development and Chief Scientific Officer at Aton Pharma. At Aton, he identified and acquired several key products and put in place its international partnerships. In addition, he was responsible for recognizing opportunities to expand the application of Aton’s products to new medical uses, and spearheaded R&D programs to develop these new indications. Before Aton, Barry was Founder and President of Park Life Science Advisory, LLC, a life sciences consulting firm, and prior to that was at consulting firm CPP Advisors (now Apeiron Partners), and the Life Sciences Group at KPMG Corporate Finance, LLP, an investment bank. For the decade prior, Barry held increasingly senior positions in cardiovascular research and then in business development at Berlex Laboratories, the US subsidiary of Schering A.G. (now Bayer Healthcare Pharmaceuticals). He began his corporate career at biotech startup Ecogen, where he founded its Protein Biochemistry Group, and served as the company’s Radiation Safety Officer.
Dr. Levinson received his PhD and Master’s degrees in Molecular Biophysics and Biochemistry from Yale University, and was granted his Bachelor of Arts, with highest honors, in Biochemistry from Princeton University. He serves on the Fidelis Board of Directors as well as that of Covis Pharmaceuticals, and is a Managing Director of Princeton Biopharma Capital Partners.
Steven Leary, DVM
Chief Medical Officer
Steven Leary, DVM, DACLAM, serves as Chief Medical Officer with Fidelis Pharmaceuticals. He received his DVM from Iowa State University and postdoctoral training in laboratory animal medicine and comparative pathology from Johns Hopkins University. Dr. Leary has 40 years’ experience, including serving as director at the University of Alabama at Birmingham and Washington University in St. Louis. He served on the AAALAC Council, as president of ACLAM, and as chair of the AVMA Animal Welfare Committee and Panels on Euthanasia, Humane Slaughter, and Depopulation. He is past recipient of the ISU Stange Award, Charles River Prize, and AALAS Griffin and Nathan R. Brewer awards.
Fidelis Pharmaceuticals Delivers Unique and Innovative Veterinary Pharmaceuticals to Address Unmet Animal Health Needs
Leaders in Long-Acting Pain Management
Fidelis Pharmaceuticals, Inc. stands ready to acquire, develop and market pharmaceutical formulations for human and veterinary medicine. Please contact a member of our team with any comments or questions.
Fidelis Pharmaceuticals, Inc.
675 Highway One, Suite B113 | North Brunswick, New Jersey 08902
Phone: 833-ETHIQAXR (833-384-4729)
©2022 Fidelis Pharmaceuticals, Inc.